Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency
virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced …

Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and
dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs …

Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …

We used genotypic and phylogenetic analysis to determine integrase diversity among
subtypes, and studied natural polymorphisms and mutations implicated in resistance to …

HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We
aimed to characterize the HIV-1 IN gene in a South African context and identify resistance …

Background Little is known about the extent and predictors of polymorphisms potentially
influencing the susceptibility to HIV integrase inhibitors (INIs). Methods Genetic sequences …

Objectives To define whether the prevalence of mutations associated with integrase inhibitor
(INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected …

The goal of this study was to explore the presence of integrase strand transfer inhibitor
(InSTI) resistance mutations in HIV-1 quasispecies present in InSTI-naïve patients and to …

Novel antiretroviral drugs offer different degrees of improvement in activity against drug-
resistant HIV, short-and long-term tolerability, and dosing convenience compared with …

Abstract HIV-1 subtype B (54.4%) and subtype F (27.2%) are the most prevalent variants in
patients who started antiretroviral therapy including an integrase inhibitor in the last 2 years …